Jerry K. L. Tan, MD, FRCPC; Jing Tang, MSc

Dr. Tan is Adjunct Professor, University of Western Ontario and Windsor Clinical Research Inc., Windsor, Ontario, Canada. Jing Tang is Statistician, Windsor Clinical Research Inc., Windsor, Ontario, Canada (currently with Fraser Health Authority, Vancouver, British Columbia, Canada) Read the rest of this article »

Erica C. Davis, MD; Valerie D. Callender, MD

Dr. Davis is from Callender Skin & Laser Center, Mitchellville, Maryland.
Dr. Callendar is from Callender Skin & Laser Center, Mitchellville, Maryland and Department of Dermatology, Howard University College of Medicine, Washington, DC. Read the rest of this article »

Lawrence F. Eichenfield, MD, Rady Children’s Hospital, San Diego, and University of California San Diego, San Diego, California; Diane Thiboutot, MD, Penn State University College of Medicine, Hershey, Pennsylvania; Alan Shalita, MD, SUNY Downstate Medical Center, Brooklyn, New York; Leonard Swinyer, MD, Dermatology Research Center, Salt Lake City, Utah; Emil Tanghetti, MD, Center for Dermatology and Laser Surgery, Sacramento, California; Eduardo Tschen, MD, Academic Dermatology Associates, Albuquerque, New Mexico; Lisa Parr, PharmD, Clinical Affairs Department, OMP, Inc., Long Beach, California Read the rest of this article »

James Q. Del Rosso, DO, FAOCD, Valley Hospital Medical Center, Las Vegas, Nevada

Abstract
Acne vulgaris is the most common disorder encountered in ambulatory clinical practice comprising 11.3 percent of office visits to dermatologists in 2005.[1] By comparison, eczematous dermatoses, psoriasis, and skin cancer accounted for 6.2, 3.5, and 10 percent of office visits, respectively.[1] A variety of topical therapeutic options are available for treatment of acne vulgaris, including benzoyl peroxide, antibiotics, retinoids, azelaic acid, and sodium sulfacetamide-sulfur.[2,3] Sodium sulfacetamide 10%-sulfur 5% has been used for the topical treatment of seborrheic dermatitis, acne vulgaris, and rosacea since the mid-1950s and is available in a variety of formulations, including lotions, creams, cleansers, and emollient foams.[4] Recently, an emollient foam sodium sulfacetamide 10%-sulfur 5% formulation indicated for topical therapy of acne vulgaris, rosacea, and seborrheic dermatitis has become available.[5] This article provides an overview of the sodium sulfacetamide 10%-sulfur 5% emollient foam and reports the results of a case report series of patients with acne vulgaris treated with sodium sulfacetamide 10%-sulfur 5% emollient foam as monotherapy or in combination with other topical acne products.

(J Clin Aesthetic Dermatol. 2009;2(8):26–29.) Read the rest of this article »

James Q. Del Rosso, DO, FAOCD
Valley Hospital Medical Center, Las Vegas, Nevada

Abstract
Objective: The study was conducted to evaluate the product attributes of a new benzoyl peroxide-containing foaming cloth cleanser and to compare the overall patient satisfaction of this product with two currently available benzoyl peroxide acne products (6% benzoyl peroxide cleanser and 4% benzoyl peroxide wash). Design: This was a randomized, single-blind study. Setting: Two clinical trial sites. Participants: Male and female subjects (N=193) aged 17 to 30 years with a history of acne vulgaris were enrolled. Measures: Subjects initially cleansed their face with the benzoyl peroxide foaming cloth and then completed a product-attribute survey. Following an interval of five minutes or more, subjects cleansed their face again using one of two randomly assigned comparator benzoyl peroxide-containing cleansing products and then completed a comparative survey. Survey results were tabulated and a top-two box analysis was performed. Results: Following the use of the benzoyl peroxide-containing foaming cloth, 94 percent of the product-attribute responses were positive (p?0.05). With respect to convenience, usability, and cosmetic elegance, the majority of subjects indicated a preference for the benzoyl peroxide foaming cloth compared to the 6% benzoyl peroxide cleanser and 4% benzoyl peroxide wash (for each, p?0.05). There were no reports of adverse events. Conclusion: These attributes supporting preference for the benzoyl peroxide foaming cloth cleanser may improve patient satisfaction with topical acne treatment resulting in improved patient compliance.  (J Clin Aesthetic Dermatol. 2009;2(7):26–29.) Read the rest of this article »

Michael H. Gold, MD
Gold Skin Care Center and Tennessee Clinical Research Center, Nashville, Tennessee Read the rest of this article »

Michael H. Gold, MD; Tennessee Clinical Research Center, Nashville, Tennessee; Anneke Andriessen; RBC Consultants, The Netherlands; Julie Biron; Tennessee Clinical Research Center, Nashville, Tennessee; Hinke Andriessen; RBC Consultants, The Netherlands Read the rest of this article »

by James Q. Del Rosso, DO, FAOCD

Dr. James Del Rosso, DO, FAOCD, is Dermatology Residency Director, Valley Hospital Medical Center; Clinical Associate Professor (Dermatology), University of Nevada School of Medicine, Las Vegas, Nevada; and Associate Professor (Dermatology), Touro University College of Osteopathic Medicine, Henderson, Nevada.

Read the rest of this article »

by James Q. Del Rosso, DO, FAOCD

Dr. James Del Rosso, DO, FAOCD, is Dermatology Residency Director, Valley Hospital Medical Center; Clinical Associate Professor (Dermatology), University of Nevada School of Medicine, Las Vegas, Nevada; and Associate Professor (Dermatology), Touro University College of Osteopathic Medicine, Henderson, Nevada.

Read the rest of this article »

by Jonette E. Keri, MD, PhD, and Adena E. Rosenblatt
Department of Dermatology, University of Miami Miller School of Medicine, Miami, Florida

Disclosure: The authors identified no conflicts of interest. Read the rest of this article »